Bullous Pemphigoid Diagnosis and Management

Clinical Presentation

• Tense bullae/blisters arise on either erythematous or normal-appearing skin, primarily affecting limbs and trunk, and can be widespread or localized 1
• The prodromal phase is characterized by pruritus, urticarial or eczematous rash, and may precede blister formation by weeks, months, or occasionally years 2
• Oral lesions occur in approximately 10-30% of patients, presenting as small blisters or erosions, primarily affecting palatal mucosa 2
• Genital mucosa may also be affected 1

Diagnostic Tests

• Skin biopsy for histopathology shows subepidermal cleft with mixed inflammatory infiltrate containing numerous eosinophils 1, 2
• Direct immunofluorescence shows linear deposits of IgG and/or C3 at the basement membrane zone 1, 2
• Serological testing, including indirect immunofluorescence and ELISA for anti-BP180 and anti-BP230 antibodies, can detect circulating autoantibodies 1
• Salt-split skin technique differentiates BP from epidermolysis bullosa acquisita and cicatricial pemphigoid, with antibodies binding to the roof of the artificial blister in BP 2
• Diagnosis can be made using direct immunofluorescence (DIF), histopathology, serological tests, and indirect immunofluorescence, with a 93% positivity rate for DIF 2

Associated Conditions

• Strong association with neurological disorders, including dementia, Parkinson's disease, cerebrovascular disease, multiple sclerosis, and epilepsy 1
• Potential drug associations, including furosemide, spironolactone, neuroleptics, and gliptins in diabetic patients 1
• Significant associations with cardiovascular diseases, which should be considered in treatment planning 3

Prognosis and Management

• Generally self-limiting disease, usually remitting within 5 years, with mortality rates between 6-41% in the modern era 2
• Elderly patients are at high risk for treatment-related adverse effects 2
• Regular monitoring of disease activity and treatment-related side effects is essential, with patients with ocular, laryngeal, or esophageal involvement requiring urgent specialist consultation 2
• The Bullous Pemphigoid Disease Area Index (BPDAI) is a standardized scoring system for disease extent and activity, evaluating skin activity and damage 4

Treatment

• First-line treatment for mild disease is superpotent topical corticosteroids (clobetasol propionate 0.05% cream/ointment) applied to the whole body except the face, or only to lesions for localized disease, twice daily until lesions heal, then continue for 2 weeks after healing, and taper, as recommended by the British Journal of Dermatology guidelines 3
• First-line treatment for generalized disease is oral corticosteroids (prednisolone) at 0.5-0.75 mg/kg/day, with higher doses not providing additional benefit, and considering less aggressive therapy for patients with significant comorbidities, as recommended by the British Journal of Dermatology guidelines 3
• Second-line options include oral corticosteroids, tetracycline + nicotinamide, dapsone (after G6PD testing), and topical immunomodulators (e.g., tacrolimus), as recommended by the British Journal of Dermatology guidelines 3
• Third-line options for resistant cases include anti-CD20 or anti-IgE monoclonal antibodies, intravenous immunoglobulins, immunoadsorption, plasma exchange, and cyclophosphamide, as supported by the British Journal of Dermatology guidelines 3

Special Considerations

• Patients with ocular involvement require urgent ophthalmology consultation to prevent blindness, while those with laryngeal involvement require ENT evaluation to prevent airway compromise, and those with esophageal involvement require gastroenterology consultation to prevent strictures, as recommended by the British Journal of Dermatology guidelines 5
• Pre-conception planning is essential, with optimization of disease control before conception, aiming for a 3-month period of remission before conception, and discontinuing teratogenic medications at least 3 months before conception, as recommended by the Gut journal and the British Journal of Dermatology guidelines 6, 3
• During pregnancy, topical corticosteroids, systemic corticosteroids at the lowest effective dose, and azathioprine (if a steroid-sparing agent is needed) are preferred medications, and methotrexate, mycophenolate mofetil, cyclophosphamide, rituximab, and JAK inhibitors should be avoided, as recommended by the Gut journal and the British Journal of Dermatology guidelines 3, 6
• Breastfeeding is the preferred method of feeding and does not affect the course of bullous disease, but methotrexate should be avoided during breastfeeding, as stated by the Gut journal 6
• Live vaccinations should be avoided within the first 6 months of life for newborns of women on anti-TNF therapy during pregnancy, and monitoring neonates for potential adverse effects from maternal medications is necessary, as advised by the Gastroenterology journal 7

Follow-up and Maintenance

• Regular monitoring of disease activity, including new lesion formation, healing of established lesions, treatment-related side effects, and disease progression to other mucosal sites, is essential, with regular follow-up visits recommended, initially every 2 weeks until disease control, then monthly for the next 3 months, and every 2 months thereafter until treatment is stopped, as recommended by the British Journal of Dermatology guidelines and other sources 8, 3
• Maintenance therapy after disease control involves reducing topical treatment to 10g once weekly for 8 months (total 12 months treatment) and gradually tapering prednisolone to the minimal effective dose for systemic treatment, as recommended by the British Journal of Dermatology guidelines 3